CCRM
Robin Quirk has held various leadership positions within the biotechnology and regenerative medicine industry, including serving as Vice President at CCRM, Chief Operating Officer at Locate Bio Ltd, Chief Executive at Locate Therapeutics Ltd, and Managing Director at RegenTec Limited. With a strong background in pharmaceutical sciences and healthcare, Robin has a PhD in Pharmaceutical Sciences and a Master of Business Administration (M.B.A.) in Healthcare. Through these roles, Robin has been involved in developing and commercializing novel technologies in advanced therapeutics, regenerative medicine, and tissue engineering.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.